Intuitive Surgical, Inc. (ISRG) Q3 FY2026 Financial Statements: Revenue $3.05B, Net income $522.80M
More for Intuitive Surgical: Company index · 10-K and 10-Q summary · 8-K filings and events
PeriodQ3 FY2026
Published
Intuitive Surgical reported revenue of $3.05 billion for Q3 FY2026, the quarter ended September 30, 2026, up 21.7% from a year earlier, with instruments and accessories, systems and services all growing. Net income attributable to Intuitive was $522.8 million, or $1.49 per diluted share, down 25.8% from $704.4 million, because the quarter carried a $450 million charge for its agreement to settle a hospital antitrust class action, which still needs court approval. On the company's own non-GAAP basis, which excludes the charge, diluted earnings per share were $3.00, up 25.0% from $2.40.
| Metric | Amount | vs. year ago |
|---|---|---|
| Revenue | $3,048,700,000 | up 21.7% |
| Net income | $522,800,000 | down 25.8% |
| Diluted EPS | $1.49 | down 23.6% |
| Antitrust settlement charge | $450,000,000 | |
| Non-GAAP diluted EPS | $3.00 | up 25.0% |
Figures link to the filing they came from. Wherever the SEC filing tags a number, that number is linked: click it and the filing opens at the exact line that prints it. Figures calculated here, such as margins, free cash flow and trailing-twelve-month totals, have no line in a filing to point to and are not linked.
About this file
| Ticker | ISRG |
|---|---|
| CIK | 0001035267 |
| Company | Intuitive Surgical, Inc. |
| Business type | industrial |
| Schema template | standard industrial (medical technology): product and service revenue and cost of revenue, gross profit, SG&A, R&D, a separately presented antitrust litigation settlement, income from operations, interest and other income, income taxes, net income with the noncontrolling-interest split, basic and diluted EPS and weighted shares; the full balance sheet including cash and investments; operating, investing and financing cash flow with capital expenditures and free cash flow; share repurchases; revenue by type (instruments and accessories, systems, services) and by geography (U.S. and outside the U.S.); and the company's own non-GAAP measures from its third-quarter 2026 earnings release |
| Reporting currency | USD |
| Converted to USD | no |
| Units | actual US dollars (not millions); per-share amounts in dollars; share counts in actual shares |
ISRG annual income statement, balance sheet and cash flow
| FY2025 | FY2024 | FY2023 | |
|---|---|---|---|
| Period start | 2025-01-01 | 2024-01-01 | 2023-01-01 |
| Period end | 2025-12-31 | 2024-12-31 | 2023-12-31 |
| Period type | fiscal year | fiscal year | fiscal year |
| Source accession | 10-K | 10-K | 10-K |
| Income statement | |||
| Product revenue | 8,492,600,000 | 7,045,000,000 | 5,956,300,000 |
| Service revenue | 1,572,100,000 | 1,307,100,000 | 1,167,800,000 |
| Total revenue | 10,064,700,000 | 8,352,100,000 | 7,124,100,000 |
| Product cost of revenue | 2,866,100,000 | 2,313,100,000 | 2,041,800,000 |
| Service cost of revenue | 556,300,000 | 404,800,000 | 352,800,000 |
| Total cost of revenue | 3,422,400,000 | 2,717,900,000 | 2,394,600,000 |
| Gross profit | 6,642,300,000 | 5,634,200,000 | 4,729,500,000 |
| Selling general and administrative | 2,385,000,000 | 2,140,000,000 | 1,963,900,000 |
| Research and development | 1,311,800,000 | 1,145,300,000 | 998,800,000 |
| Total operating expenses | 3,696,800,000 | 3,285,300,000 | 2,962,700,000 |
| Income from operations | 2,945,500,000 | 2,348,900,000 | 1,766,800,000 |
| Interest and other income net | 365,900,000 | 324,900,000 | 192,100,000 |
| Income before taxes | 3,311,400,000 | 2,673,800,000 | 1,958,900,000 |
| Income tax expense | 434,800,000 | 336,300,000 | 141,600,000 |
| Net income | 2,876,600,000 | 2,337,500,000 | 1,817,300,000 |
| Net income attributable to noncontrolling interest | 20,600,000 | 14,900,000 | 19,300,000 |
| Net income attributable to intuitive surgical | 2,856,000,000 | 2,322,600,000 | 1,798,000,000 |
| Basic EPS | 8.00 | 6.54 | 5.12 |
| Diluted EPS | 7.87 | 6.42 | 5.03 |
| Basic shares | 356,900,000 | 355,200,000 | 351,200,000 |
| Diluted shares | 362,700,000 | 362,000,000 | 357,400,000 |
| Balance sheet | |||
| Cash and cash equivalents | 3,368,000,000 | 2,027,400,000 | |
| Short term investments | 2,566,900,000 | 1,985,900,000 | |
| Accounts receivable net | 1,527,300,000 | 1,225,400,000 | |
| Inventory | 1,840,000,000 | 1,487,200,000 | |
| Prepaids and other current assets | 477,300,000 | 385,100,000 | |
| Total current assets | 9,779,500,000 | 7,111,000,000 | |
| Property plant and equipment net | 5,342,400,000 | 4,646,600,000 | |
| Long term investments | 3,099,200,000 | 4,819,100,000 | |
| Deferred tax assets | 1,018,600,000 | 1,045,100,000 | |
| Intangible and other assets net | 848,700,000 | 773,900,000 | |
| Goodwill | 370,300,000 | 347,500,000 | |
| Total assets | 20,458,700,000 | 18,743,200,000 | |
| Accounts payable | 255,100,000 | 193,400,000 | |
| Accrued compensation and employee benefits | 648,400,000 | 535,600,000 | |
| Deferred revenue | 506,700,000 | 468,800,000 | |
| Other accrued liabilities | 596,000,000 | 547,500,000 | |
| Total current liabilities | 2,006,200,000 | 1,745,300,000 | |
| Other long term liabilities | 510,800,000 | 468,300,000 | |
| Total liabilities | 2,517,000,000 | 2,213,600,000 | |
| Additional paid in capital | 10,768,500,000 | 9,681,300,000 | |
| Retained earnings | 7,011,800,000 | 6,803,300,000 | |
| Accumulated other comprehensive income loss | 43,300,000 | -51,300,000 | |
| Total intuitive surgical stockholders equity | 17,824,000,000 | 16,433,700,000 | |
| Noncontrolling interest in joint venture | 117,700,000 | 95,900,000 | |
| Total stockholders equity | 17,941,700,000 | 16,529,600,000 | |
| Common shares outstanding | 355,100,000 | 356,600,000 | |
| Cash cash equivalents and investments | 9,034,100,000 | 8,832,400,000 | |
| Cash flow | |||
| Depreciation and loss on disposal of property plant and equipment | 614,700,000 | 445,300,000 | 401,600,000 |
| Amortization of intangible and other assets | 62,400,000 | 54,400,000 | 53,200,000 |
| Deferred income taxes | 19,100,000 | -135,300,000 | -280,800,000 |
| Share based compensation | 788,200,000 | 676,800,000 | 592,800,000 |
| Operating cash flow | 3,030,500,000 | 2,415,000,000 | 1,813,800,000 |
| Purchases of investments | -1,215,900,000 | -5,139,600,000 | -2,207,400,000 |
| Proceeds from sales of investments | 259,900,000 | 100,200,000 | 230,300,000 |
| Proceeds from maturities of investments | 2,175,500,000 | 2,878,800,000 | 2,690,100,000 |
| Capital expenditures | -539,800,000 | -1,111,200,000 | -1,064,200,000 |
| Acquisitions net of cash intellectual property and other investing | -13,900,000 | -1,000,000 | -8,900,000 |
| Net cash from investing activities | 665,800,000 | -3,272,800,000 | -360,100,000 |
| Proceeds from employee stock plans | 350,300,000 | 429,400,000 | 296,300,000 |
| Taxes paid for net share settlement of equity awards | -419,100,000 | -270,000,000 | -164,700,000 |
| Repurchases of common stock | -2,295,300,000 | 0 | -416,300,000 |
| Net cash from financing activities | -2,364,100,000 | 150,900,000 | -287,600,000 |
| Effect of exchange rate changes | 12,800,000 | -800,000 | 3,300,000 |
| Net change in cash cash equivalents and restricted cash | 1,345,000,000 | -707,700,000 | 1,169,400,000 |
| Cash cash equivalents and restricted cash end of period | 3,407,400,000 | 2,062,400,000 | 2,770,100,000 |
| Free cash flow | 2,490,700,000 | 1,303,800,000 | 749,600,000 |
| Revenue by type | |||
| Instruments and accessories | 6,018,900,000 | 5,079,000,000 | 4,276,600,000 |
| Systems | 2,473,700,000 | 1,966,000,000 | 1,679,700,000 |
| Services | 1,572,100,000 | 1,307,100,000 | 1,167,800,000 |
| Total revenue | 10,064,700,000 | 8,352,100,000 | 7,124,100,000 |
| Revenue by geography | |||
| United states | 6,815,800,000 | 5,589,400,000 | 4,688,600,000 |
| Outside united states | 3,248,900,000 | 2,762,700,000 | 2,435,500,000 |
ISRG quarterly income statement, balance sheet and cash flow
| Q3 FY2026 | Q3 FY2025 | |
|---|---|---|
| Fiscal quarter | 3 | 3 |
| Period start | 2026-07-01 | 2025-07-01 |
| Period end | 2026-09-30 | 2025-09-30 |
| Period type | three months | three months |
| Source accession | 10-Q | 10-Q |
| Income statement | ||
| Product revenue | 2,566,500,000 | 2,109,200,000 |
| Service revenue | 482,200,000 | 395,900,000 |
| Total revenue | 3,048,700,000 | 2,505,100,000 |
| Product cost of revenue | 797,700,000 | 699,400,000 |
| Service cost of revenue | 166,700,000 | 143,300,000 |
| Total cost of revenue | 964,400,000 | 842,700,000 |
| Gross profit | 2,084,300,000 | 1,662,400,000 |
| Selling general and administrative | 633,400,000 | 573,300,000 |
| Antitrust class action litigation settlement | 450,000,000 | 0 |
| Research and development | 408,300,000 | 329,400,000 |
| Total operating expenses | 1,491,700,000 | 902,700,000 |
| Income from operations | 592,600,000 | 759,700,000 |
| Interest and other income net | 75,800,000 | 95,500,000 |
| Income before taxes | 668,400,000 | 855,200,000 |
| Income tax expense | 144,000,000 | 146,000,000 |
| Net income | 524,400,000 | 709,200,000 |
| Net income attributable to noncontrolling interest | 1,600,000 | 4,800,000 |
| Net income attributable to intuitive surgical | 522,800,000 | 704,400,000 |
| Basic EPS | 1.50 | 1.98 |
| Diluted EPS | 1.49 | 1.95 |
| Basic shares | 349,000,000 | 356,600,000 |
| Diluted shares | 351,600,000 | 361,800,000 |
| Balance sheet | ||
| Cash and cash equivalents | 2,978,100,000 | |
| Short term investments | 1,064,400,000 | |
| Accounts receivable net | 1,721,300,000 | |
| Inventory | 2,128,200,000 | |
| Prepaids and other current assets | 536,300,000 | |
| Total current assets | 8,428,300,000 | |
| Property plant and equipment net | 5,676,200,000 | |
| Long term investments | 2,757,900,000 | |
| Deferred tax assets | 719,700,000 | |
| Intangible and other assets net | 1,209,200,000 | |
| Goodwill | 557,800,000 | |
| Total assets | 19,349,100,000 | |
| Accounts payable | 279,500,000 | |
| Accrued compensation and employee benefits | 505,900,000 | |
| Deferred revenue | 541,200,000 | |
| Other accrued liabilities | 1,206,400,000 | |
| Total current liabilities | 2,533,000,000 | |
| Other long term liabilities | 698,300,000 | |
| Total liabilities | 3,231,300,000 | |
| Additional paid in capital | 11,521,100,000 | 10,478,800,000 |
| Retained earnings | 4,525,100,000 | 6,424,000,000 |
| Accumulated other comprehensive income loss | -60,300,000 | 26,500,000 |
| Total intuitive surgical stockholders equity | 15,986,200,000 | 16,929,700,000 |
| Noncontrolling interest in joint venture | 131,600,000 | 112,400,000 |
| Total stockholders equity | 16,117,800,000 | 17,042,100,000 |
| Common shares outstanding | 346,600,000 | 354,900,000 |
| Cash cash equivalents and investments | 6,800,400,000 | |
| Revenue by type | ||
| Instruments and accessories | 1,797,400,000 | 1,518,800,000 |
| Systems | 769,100,000 | 590,400,000 |
| Services | 482,200,000 | 395,900,000 |
| Total revenue | 3,048,700,000 | 2,505,100,000 |
| Revenue by geography | ||
| United states | 2,063,000,000 | 1,717,600,000 |
| Outside united states | 985,700,000 | 787,500,000 |
| Shareholder returns | ||
| Shares repurchased | 7,800,000 | 4,000,000 |
| Average price per share repurchased | 377.01 | 479.60 |
| Aggregate cost of shares repurchased | 2,939,800,000 | 1,919,600,000 |
| Non GAAP | ||
| Non GAAP gross profit | 2,129,600,000 | 1,703,800,000 |
| Non GAAP income from operations | 1,269,700,000 | 975,900,000 |
| Non GAAP net income attributable to intuitive surgical | 1,054,500,000 | 867,200,000 |
| Non GAAP diluted EPS | 3.0 | 2.4 |
| Non GAAP source accession | 0001035267-26-000067 | 0001035267-26-000067 |
- Balance sheet source, Q3 FY2025. The Q3 2026 10-Q prints no September 30, 2025 balance sheet; the equity figures and shares outstanding shown for Q3 FY2025 are the September 30, 2025 ending balances in that 10-Q's stockholders' equity note (Note 9).
ISRG year-to-date income statement and cash flow
| Nine months ended September 30, 2026 | Nine months ended September 30, 2025 | |
|---|---|---|
| Period start | 2026-01-01 | 2025-01-01 |
| Period end | 2026-09-30 | 2025-09-30 |
| Period type | nine months | nine months |
| Source accession | 10-Q | 10-Q |
| Income statement | ||
| Product revenue | 7,323,500,000 | 6,048,400,000 |
| Service revenue | 1,388,300,000 | 1,150,100,000 |
| Total revenue | 8,711,800,000 | 7,198,500,000 |
| Product cost of revenue | 2,354,700,000 | 2,056,300,000 |
| Service cost of revenue | 481,900,000 | 404,200,000 |
| Total cost of revenue | 2,836,600,000 | 2,460,500,000 |
| Gross profit | 5,875,200,000 | 4,738,000,000 |
| Selling general and administrative | 1,864,600,000 | 1,697,900,000 |
| Antitrust class action litigation settlement | 450,000,000 | 0 |
| Research and development | 1,140,800,000 | 958,900,000 |
| Total operating expenses | 3,455,400,000 | 2,656,800,000 |
| Income from operations | 2,419,800,000 | 2,081,200,000 |
| Interest and other income net | 243,600,000 | 274,600,000 |
| Income before taxes | 2,663,400,000 | 2,355,800,000 |
| Income tax expense | 489,800,000 | 278,700,000 |
| Net income | 2,173,600,000 | 2,077,100,000 |
| Net income attributable to noncontrolling interest | 11,200,000 | 15,900,000 |
| Net income attributable to intuitive surgical | 2,162,400,000 | 2,061,200,000 |
| Basic EPS | 6.13 | 5.77 |
| Diluted EPS | 6.07 | 5.67 |
| Basic shares | 352,600,000 | 357,500,000 |
| Diluted shares | 356,200,000 | 363,500,000 |
| Cash flow | ||
| Depreciation and loss on disposal of property plant and equipment | 559,000,000 | 446,300,000 |
| Amortization of intangible and other assets | 85,000,000 | 37,300,000 |
| Deferred income taxes | 315,900,000 | 58,600,000 |
| Share based compensation | 632,000,000 | 584,900,000 |
| Operating cash flow | 3,197,000,000 | 2,138,000,000 |
| Purchases of investments | -1,460,300,000 | -790,900,000 |
| Proceeds from sales of investments | 1,845,100,000 | 249,100,000 |
| Proceeds from maturities of investments | 1,373,500,000 | 1,795,500,000 |
| Proceeds from sale of assets | 46,000,000 | 0 |
| Capital expenditures | -329,000,000 | -377,300,000 |
| Acquisitions net of cash intellectual property and other investing | -518,600,000 | -1,200,000 |
| Net cash from investing activities | 956,700,000 | 875,200,000 |
| Proceeds from employee stock plans | 283,800,000 | 273,700,000 |
| Taxes paid for net share settlement of equity awards | -378,500,000 | -406,000,000 |
| Repurchases of common stock | -4,419,200,000 | -2,094,300,000 |
| Other financing activities | -21,300,000 | 0 |
| Net cash from financing activities | -4,535,200,000 | -2,226,600,000 |
| Effect of exchange rate changes | -3,500,000 | 500,000 |
| Net change in cash cash equivalents and restricted cash | -385,000,000 | 787,100,000 |
| Cash cash equivalents and restricted cash end of period | 3,022,400,000 | 2,849,500,000 |
| Free cash flow | 2,868,000,000 | 1,760,700,000 |
| Revenue by type | ||
| Instruments and accessories | 5,218,700,000 | 4,360,600,000 |
| Systems | 2,104,800,000 | 1,687,800,000 |
| Services | 1,388,300,000 | 1,150,100,000 |
| Total revenue | 8,711,800,000 | 7,198,500,000 |
| Revenue by geography | ||
| United states | 5,779,500,000 | 4,885,200,000 |
| Outside united states | 2,932,300,000 | 2,313,300,000 |
| Shareholder returns | ||
| Shares repurchased | 11,000,000 | 4,400,000 |
| Average price per share repurchased | 405.51 | 482.66 |
| Aggregate cost of shares repurchased | 4,446,300,000 | 2,100,600,000 |
| Non GAAP | ||
| Non GAAP gross profit | 6,032,600,000 | 4,857,500,000 |
| Non GAAP income from operations | 3,564,500,000 | 2,690,000,000 |
| Non GAAP net income attributable to intuitive surgical | 2,957,700,000 | 2,326,600,000 |
| Non GAAP diluted EPS | 8.3 | 6.4 |
| Non GAAP source accession | 0001035267-26-000067 | 0001035267-26-000067 |
ISRG trailing twelve month income statement and cash flow
| Twelve months ended September 30, 2026 | |
|---|---|
| Period start | 2025-10-01 |
| Period end | 2026-09-30 |
| Period type | trailing twelve months |
| Source accession | 10-Q |
| Derived from accessions | 10-K, 10-Q |
| Income statement | |
| Product revenue | 9,767,700,000 |
| Service revenue | 1,810,300,000 |
| Total revenue | 11,578,000,000 |
| Product cost of revenue | 3,164,500,000 |
| Service cost of revenue | 634,000,000 |
| Total cost of revenue | 3,798,500,000 |
| Gross profit | 7,779,500,000 |
| Selling general and administrative | 2,551,700,000 |
| Research and development | 1,493,700,000 |
| Total operating expenses | 4,495,400,000 |
| Income from operations | 3,284,100,000 |
| Interest and other income net | 334,900,000 |
| Income before taxes | 3,619,000,000 |
| Income tax expense | 645,900,000 |
| Net income | 2,973,100,000 |
| Net income attributable to noncontrolling interest | 15,900,000 |
| Net income attributable to intuitive surgical | 2,957,200,000 |
| Antitrust class action litigation settlement | 450,000,000 |
| Cash flow | |
| Operating cash flow | 4,089,500,000 |
| Capital expenditures | -491,500,000 |
| Share based compensation | 835,300,000 |
| Repurchases of common stock | -4,620,200,000 |
| Free cash flow | 3,598,000,000 |
| Revenue by type | |
| Instruments and accessories | 6,877,000,000 |
| Systems | 2,890,700,000 |
| Services | 1,810,300,000 |
| Total revenue | 11,578,000,000 |
Adjustments
| Splits applied | none |
|---|---|
| ADR ratio | n/a |
| FX | none; Intuitive Surgical reports in US dollars |
| Split note | Intuitive Surgical's 3-for-1 stock split took effect in October 2021, before every period shown here, so all per-share figures and share counts are already on a post-split basis and none have been adjusted. |
Notes
- Annual figures for FY2023, FY2024 and FY2025 are from the FY2025 Form 10-K (accession 0001035267-26-000010), which prints three years of income and cash flow statements and two year-end balance sheets (December 31, 2025 and 2024); FY2023 therefore carries no balance sheet.
- Quarterly figures for the three months ended September 30, 2026 and 2025, the nine-month year-to-date figures and the September 30, 2026 balance sheet are from the Q3 2026 Form 10-Q (accession 0001035267-26-000071). The December 31, 2025 balance sheet column the 10-Q reprints matches the 10-K line for line.
- Q3 2026 results include a $450.0 million pre-tax charge for the settlement of the antitrust class action litigation ("In re: da Vinci Surgical Robot Antitrust Litigation"), which the 10-Q presents as a separate operating-expense line. The earnings release instead includes it within selling, general and administrative expense, which it reports as $1,083.4 million for the quarter ($633.4 million plus the $450.0 million settlement). The release states the charge was $347 million net of tax, or $0.99 per diluted share, and that the settlement remains subject to court approval. This charge is why Q3 2026 income from operations ($592.6 million) fell from Q3 2025 ($759.7 million) while revenue rose 22%.
- The 10-Q prints cash flows for the nine months only, so the quarterly entries carry no cash flow figures; nine-month cash flows are in the year-to-date block.
- The balance sheets present no debt or borrowings line, so no total-debt figure is shown. The company paid no dividends; the only dividend line on the cash flow statement is the joint venture's $8.0 million payment to its noncontrolling holder in FY2024.
- Cash flow outflows are stored as negative numbers, as the statements print them in parentheses.
- The trailing-twelve-month block is computed as FY2025 plus the nine months ended September 30, 2026 less the nine months ended September 30, 2025; per-share figures and share counts are not computed for it. Its SG&A excludes the $450.0 million settlement, which is shown on its own line.
- Non-GAAP figures for Q3 2026, Q3 2025 and both nine-month periods are the company's own, from the GAAP to non-GAAP reconciliation in its Q3 2026 earnings release (accession 0001035267-26-000067); they are not GAAP measures.
Uncertainties
- Three-month cash flow figures for Q3 2026 and Q3 2025 (operating cash flow, capital expenditures, free cash flow) are not available: the Q3 2026 10-Q prints only nine-month cash flows, and the six-month figures needed to difference them are in the Q2 2026 10-Q, which is not among the filings read for this page.
- The FY2025 10-K has no separate litigation-settlement line, so FY2025 SG&A includes whatever litigation charges arose that year; the earnings release attributes $454.9 million of Q3 2026 litigation charges to SG&A, of which $450.0 million is the antitrust settlement shown separately in the 10-Q.
Definitions
| Net income | Consolidated net income, including the share earned by the noncontrolling interest in the company's joint venture with Fosun Pharma. Earnings per share are struck on net_income_attributable_to_intuitive_surgical. |
|---|---|
| Antitrust class action litigation settlement | The $450.0 million charge for the settlement of the antitrust class action litigation, which the Q3 2026 10-Q presents as its own operating-expense line. Zero where the 10-Q prints a dash; not presented in the FY2025 10-K. |
| Free cash flow | Net cash provided by operating activities less purchases of property, plant, and equipment. Computed here from the cash flow statement; it is not a figure the company reports. |
| Capital expenditures | Purchases of property, plant, and equipment as printed on the cash flow statement (shown as a negative outflow). |
| Cash cash equivalents and investments | Cash and cash equivalents plus short-term and long-term investments, summed from the balance sheet. The company's Q3 2026 earnings release prints the same total: $6,800.4 million at September 30, 2026 and $9,034.1 million at December 31, 2025. |
| Common shares outstanding | Common shares issued and outstanding at the period end, from the stockholders' equity statement. |
| Revenue by type | Revenue disaggregated by type in the revenue note: instruments and accessories plus systems make up product revenue; services equals service revenue. |
| Non GAAP | The company's own non-GAAP measures from its Q3 2026 earnings release (Exhibit 99.1 to the Form 8-K, accession 0001035267-26-000067). They exclude share-based compensation and long-term incentive plan expense, amortization of intangible assets, litigation charges (including the $450 million antitrust settlement), acquisition-related items, gains on sale of businesses and assets, gains or losses on strategic investments and tax adjustments, as the release defines them. |
| Trailing twelve months | FY2025 from the FY2025 10-K plus the nine months ended September 30, 2026, less the nine months ended September 30, 2025, both from the Q3 2026 10-Q. |
Company details
| Name | Intuitive Surgical Inc |
|---|---|
| Ticker | ISRG |
| CIK | 0001035267 |
| Exchange | Nasdaq |
| State | California |
| Incorporation | Delaware |
| SIC | 3842 |
| Office | Industrial Applications and Services |
| Industry | Orthopedic, Prosthetic & Surgical Appliances & Supplies |
Fiscal period
| Fiscal year | 2026 |
|---|---|
| Fiscal period | Q3 |
| Tag | FY26Q3 |
| Period end | 2026-09-30 |
| Form | 10-Q |
| Accession | 0001035267-26-000071 |
| Fiscal year end | 1231 |
| Source | facts |
Source filings
| Role | Current | Form | Fiscal year | Fiscal period | Tag | Period end | Filed | Accession | Source |
|---|---|---|---|---|---|---|---|---|---|
| annual | no | 10-K | 2025 | FY | FY25 | 2025-12-31 | 2026-02-03 | 0001035267-26-000010 | reported |
| quarterly | yes | 10-Q | 2026 | Q3 | FY26Q3 | 2026-09-30 | 2026-10-21 | 0001035267-26-000071 | facts |
FAQ · Intuitive Surgical financial statements
How much revenue did Intuitive Surgical report in Q3 FY2026?
Intuitive Surgical reported revenue of $3.05 billion for Q3 FY2026, the quarter ended September 30, 2026. That is up 21.7% from $2.51 billion in the same quarter a year earlier.
Why did Intuitive Surgical's earnings fall in Q3 FY2026?
Intuitive Surgical's net income attributable to the company fell to $522.8 million in Q3 FY2026, down 25.8% from $704.4 million a year earlier, and diluted earnings per share fell to $1.49 from $1.95. The decline reflects a $450 million operating-expense charge, recorded in the quarter, for settling a hospital antitrust class action, while revenue was up 21.7% from a year earlier.
What is Intuitive Surgical's antitrust class action settlement?
Intuitive Surgical agreed after the quarter to make a one-time payment of $450 million to settle the hospital class action known as In re: da Vinci Surgical Robot Antitrust Litigation, with agreed injunctive relief and no admission of liability. The company recorded the full amount as an operating-expense charge and a liability for the quarter ended September 30, 2026, and the settlement still needs preliminary and final court approval.
What was Intuitive Surgical's non-GAAP EPS in Q3 FY2026?
Intuitive Surgical reported non-GAAP diluted earnings per share of $3.00 for Q3 FY2026, up 25.0% from $2.40 a year earlier, compared with GAAP diluted earnings per share of $1.49. The company's non-GAAP measure excludes items including the antitrust settlement charge, share-based compensation and amortization of intangible assets.
Where can I get Intuitive Surgical, Inc. (ISRG) financial data in machine-readable form?
Ticker Scout publishes Intuitive Surgical, Inc.'s financial statements as JSON at https://tickerscout.ai/isrg/financials.json, free, with no API key and no signup. The 10-K and 10-Q narrative and the 8-K events digest are published as Markdown at https://tickerscout.ai/isrg/narrative.md and https://tickerscout.ai/isrg/events.md. Intuitive Surgical, Inc.'s SEC CIK is 0001035267. Every figure cites the SEC accession number it came from, so it can be checked against sec.gov.
When does Intuitive Surgical, Inc. (ISRG) next file with the SEC?
Intuitive Surgical, Inc. (ISRG) is expected to file its next Form 10-K with the SEC on or around February 2, 2027. That date is a projection rather than a company-announced date: it is derived from Intuitive Surgical, Inc.'s own filing history with the SEC, by taking the date the company filed the same fiscal period a year earlier and adding 52 weeks. The most recent periodic report on file is the 10-Q for Q3 FY2026, the period ended 2026-09-30, SEC accession 0001035267-26-000071.
Related companies
How this page was built
This page was built from three of Intuitive Surgical, Inc.'s own filings with the SEC, read one at a time. Nothing on it is taken from a pre-tagged dataset, a data vendor or another website. The figures are on the company's own fiscal calendar and in actual dollars, as the filings report them. Where the filings do not support a figure, the record says so instead of reporting a zero; this period names two such gaps.
A single company files thousands of pages with the SEC in a year, and no two companies file them the same way, so the reading and the assembly here are done by AI rather than by rules that break on the differences. Every pass is then audited back against the filings it came from before the page is published, and anything the filings do not support is left out and named rather than filled in. AI can still make mistakes. That is why the accession numbers are printed: the filing is the authority, and this page is a route to it.
Published by Ticker Scout, an independent publisher of company filings data. About Ticker Scout · Disclaimer
Built from Intuitive Surgical, Inc.'s SEC filings by Ticker Scout; accession numbers are cited throughout so every figure can be checked against sec.gov. Free to cite with attribution: Ticker Scout (tickerscout.ai). Not investment advice, see the Disclaimer.